Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medigen Vaccine Biologics's share price is NT$68.10.
Medigen Vaccine Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1.77. Hence, Medigen Vaccine Biologics's PS Ratio for today is 38.54.
Warning Sign:
Medigen Vaccine Biologics Corp stock PS Ratio (=34.8) is close to 2-year high of 36.79.
The historical rank and industry rank for Medigen Vaccine Biologics's PS Ratio or its related term are showing as below:
ROCO:6547'
s PS Ratio Range Over the Past 10 Years
Min: 7.79 Med: 42.66 Max: 10696.02
Current: 38.54
During the past 13 years, Medigen Vaccine Biologics's highest PS Ratio was 10696.02. The lowest was 7.79. And the median was 42.66.
ROCO:6547's PS Ratio is ranked worse than 75.43% of 936
companies
in the Biotechnology industry
Industry Median: 9.545
vs ROCO:6547: 38.54
During the past 13 years, Medigen Vaccine Biologics's highest 3-Year average Revenue per Share Growth Rate was 508.90% per year. The lowest was -50.40% per year. And the median was 112.65% per year.
Medigen Vaccine Biologics (ROCO:6547) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medigen Vaccine Biologics PS Ratio Related Terms
Medigen Vaccine Biologics PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medigen Vaccine Biologics's Share Price of today is NT$68.10. Medigen Vaccine Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medigen Vaccine Biologics (ROCO:6547) has a PS Ratio of 38.54 as of Sep. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medigen Vaccine Biologics and its competitors. This is 10% below median its historical median of 42.66. Over the past decade, Medigen Vaccine Biologics' PS Ratio has ranged from 7.79 to 10,696.02. According to the industry distribution chart, Medigen Vaccine Biologics ranks #706 out of 936 companies in the Biotechnology industry, placing it in the top 75.4%.
Is Medigen Vaccine Biologics' PS Ratio too high?
Medigen Vaccine Biologics' current PS Ratio of 38.54 is 10% below median its 10-year median of 42.66. Over the past 10 years, this metric has ranged from a low of 7.79 to a high of 10,696.02. The Biotechnology industry median PS Ratio is 9.55. Medigen Vaccine Biologics' value of 38.54 is 303.8% above this industry median. Based on the distribution chart, Medigen Vaccine Biologics ranks #706 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #706 out of 936 companies for PS Ratio. This places Medigen Vaccine Biologics in the lower half of its industry. The industry median PS Ratio is 9.55. Medigen Vaccine Biologics' value of 38.54 is 303.8% above this benchmark. Historically, Medigen Vaccine Biologics' own PS Ratio has ranged from 7.79 to 10,696.02 over the past decade. While the company's 10-year median is 42.66 vs. the industry median of 9.55, Medigen Vaccine Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current PS Ratio of 38.54 is 303.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current PS Ratio is 38.54, which is 10% below median its own 10-year median of 42.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$54.99, compared to a current price of NT$68.10 — trading 23.8% above its estimated fair value. The current PS Ratio is 38.54, which is 10% below median its 10-year median of 42.66 and 303.8% above the Biotechnology industry median of 9.55. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current PS Ratio is 38.54 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be overvalued.
The current stock price of NT$68.10 is trading 23.8% above its estimated GF Value™ of NT$54.99.
GuruFocus considers Medigen Vaccine Biologics to be Modestly Overvalued.
Key valuation signals for ROCO:6547:
PS Ratio: 38.54 (10% below median its 10-year median of 42.66)
GF Value™: NT$54.99 vs. price of NT$68.10 (23.8% above fair value)
Industry Position: 303.8% above the Biotechnology median (#706 of 936)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score
Get the complete analysis for ROCO:6547
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
